Can We Override Clopidogrel Resistance? [PDF]
Circulation, 2009 Clopidogrel, a thienopyridine antiplatelet agent, has been used alone or in association with aspirin to prevent vascular complications in atherothrombotic patients. It is also, in combination with aspirin, the key treatment to prevent stent thrombosis in patients who have undergone percutaneous coronary intervention.
Ana, Pena +7 more
openaire +2 more sources
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]
, 2018 © The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast +66 more
core +2 more sources
Effect of obesity and serum leptin level on clopidogrel resistance
Türk Kardiyoloji Derneği Arşivi, 2016 Objective: Clopidogrel inhibits platelet aggregation by blockade of platelet adenosine diphosphate (ADP) P2Y12 receptor. Leptin is the obesity gene product, and its serum level increases with obesity.
Ali Dogan +5 more
doaj +1 more source
Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience [PDF]
Neurointervention, 2019 Purpose A safe and efficacious antiplatelet drug is needed for patients with clopidogrel resistance who undergo neuroendovascular procedures. Ticagrelor is a new reversibly binding, oral, direct-acting P2Y receptor antagonist with no known resistance. We
Vivek Karan +3 more
doaj +1 more source
Coming safely to a stop : a review of platelet activity after cessation of antiplatelet drugs [PDF]
, 2015 Funding Isobel Ford is an employee of the University of Aberdeen. The research for the writing of this review received no specific grant from any funding agency in the public, commercial, or not-forprofit sectorsPeer ...
Ford, Isobel
core +1 more source
ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION
Рациональная фармакотерапия в кардиологии, 2016 Aim. To evaluate the incidence of acetylsalicylic acid (ASA) and clopidogrel resistance in patients with acute coronary syndrome with ST-segment elevation and to find out possible clinical factors, contributing to this state.Material and methods.
D. H. Ainetdinova +2 more
doaj +1 more source
Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. [PDF]
, 2017 BackgroundElevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.Methods and resultsBaseline demographics and 2-year MACE were ...
Ang, Lawrence +7 more
core +1 more source
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]
, 2019 © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A +5 more
core +2 more sources
Clinical application of high throughput molecular screening techniques for pharmacogenomics. [PDF]
, 2011 Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples.
Schrijver, Iris, Wiita, Arun P
core +1 more source